Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort.

ABSTRACT:

Purpose

There are new advancements in the modulation of the treatment of patients with early-stage breast cancer, including the use of several molecular profiling tests to identify or select those patients who require additional adjuvant chemotherapy together with hormonal therapy on the basis of a recurrence score. One such tool is EndoPredict (Myriad Genetics; Salt Lake City, UT), which provides support in clinical decision making. The objective of this analysis was to study the landscape of absolute chemotherapy benefit and the likelihood of recurrence within 5 to 15 years in Indian patients with breast cancer who are undergoing EndoPredict testing.

Patients and methods

This study included 308 patients with hormone-positive, human epidermal growth factor receptor 2-negati

SUBMITTER: Somashekhar SP 

PROVIDER: S-EPMC7529538 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature